A Retrospective Observational Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US

被引：0
|
作者：
Cockerham, Alex [1 ]
Wilson, Amanda [2 ]
Frick, Andrew [3 ]
Dasmahapatra, Pronabesh [2 ]
机构：
[1] Sanofi, Brookline, MA USA
[2] Sanofi, Cambridge, MA USA
[3] Trio Hlth, San Diego, CA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148325
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3031
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [1] Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    Powell, Jerry S.
    Josephson, Neil C.
    Quon, Doris
    Ragni, Margaret V.
    Cheng, Gregory
    Li, Ella
    Jiang, Haiyan
    Li, Lian
    Dumont, Jennifer A.
    Goyal, Jaya
    Zhang, Xin
    Sommer, Jurg
    McCue, Justin
    Barbetti, Margaret
    Luk, Alvin
    Pierce, Glenn F.
    BLOOD, 2012, 119 (13) : 3031 - 3037
  • [2] Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
    Powell, Jerry S.
    Pasi, K. John
    Ragni, Margaret V.
    Ozelo, Margareth C.
    Valentino, Leonard A.
    Mahlangu, Johnny N.
    Josephson, Neil C.
    Perry, David
    Manco-Johnson, Marilyn J.
    Apte, Shashikant
    Baker, Ross I.
    Chan, Godfrey C.
    Novitzky, Nicolas
    Wong, Raymond S.
    Krassova, Snejana
    Allen, Geoffrey
    Jiang, Haiyan
    Innes, Alison
    Li, Shuanglian
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Nugent, Karen
    Vigliani, Gloria
    Brennan, Aoife
    Luk, Alvin
    Pierce, Glenn F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24): : 2313 - 2323
  • [3] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2014, 123 (03) : 317 - 325
  • [4] Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A
    Ebbert, Patrick T.
    Xavier, Frederico
    Malec, Lynn M.
    Seaman, Craig D.
    Ragni, Margaret, V
    THROMBOSIS RESEARCH, 2020, 195 : 51 - 54
  • [5] Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors
    Ebbert, Patrick T.
    Ragni, Margaret V.
    Xavier, Frederico
    Malec, Lynn M.
    Seaman, Craig D.
    BLOOD, 2017, 130
  • [6] Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A
    Sattler, Laurent
    Raissi, Ahlem
    Fornoff, Damien
    Gerout, Anne-Cecile
    Feugeas, Olivier
    Grunebaum, Lelia
    Desprez, Dominique
    ANNALES DE BIOLOGIE CLINIQUE, 2020, 78 (01) : 35 - 46
  • [7] Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients
    Liu, Bin
    Wang, Xiaoshan
    Li, Xueqin
    Yan, Haixia
    Wang, Shuya
    Zhu, Xi
    Wang, Pengju
    Gao, Jie
    Wang, Yali
    Su, Hongsheng
    BLOOD, 2018, 132
  • [8] A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)
    Konkle, Barbara A.
    Quon, Doris, V
    Raffini, Leslie
    Recht, Michael
    Radulescu, Vlad C.
    Carpenter, Shannon L.
    Dunn, Amy L.
    Lu, Mei
    Watt, Maureen
    JOURNAL OF BLOOD MEDICINE, 2021, 12 : 883 - 896
  • [9] Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein Treatment of hemophilia A
    Villarreal-Martinez, Laura
    Zamora-Martinez, Paola Lizeth
    DRUGS OF THE FUTURE, 2022, 47 (10) : 711 - 714
  • [10] STUDY OF COST EFFECTIVENESS OF THE RECOMBINANT COAGULATION FACTOR IX UNITED TO PROTEIN FC FOR THE TREATMENT OF HEMOPHILIA B IN CHILE
    Balmaceda, C.
    Vargas, C.
    Rodriguez, F.
    Rojas, R.
    Espinoza, M. A.
    VALUE IN HEALTH, 2017, 20 (09) : A895 - A895
12345